For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
The advantages of RabMAb® primary antibodies stem from the uniqueness of the rabbit immune system.
Our RabMAb® technology enables the development of high-affinity, high-specificity antibodies to challenging targets. Ourselves and others have observed that compared to mice and other rodents, rabbits:
In addition, the rabbit spleen, the typical source of antibody-producing cells for generation of hybridomas, is larger and contains more cells than a mouse spleen.
The combination of these properties results in a wider range of antibodies and therefore a better chance of finding the right experimental tools than with traditional technologies.
Rabbit monoclonals, for example, have on average 10-100x higher affinity than mouse monoclonals and are often better at detecting subtle differences such as slight sequence variations that distinguish members of a protein family.
The rabbit immune system is capable of generating greater antibody diversity through: